Unhidea explains global investment research, selected interviews and market briefs. Explore source attribution, dates, key assumptions and the reasoning behind each article.
In the first three quarters of 2026, new orders for WuXi AppTec’s continuing operations rose more than 60% year over year at constant exchange rates. Citi raised its earnings forecasts and target prices while factoring in the potential erosion of chemistry gross margins from new capacity.
Citi ·
Third-quarter profit grew faster than revenue, and the company raised its full-year guidance again. JPMorgan sees growth from late-stage projects and commercial manufacturing, but the timing of large-order deliveries and the ramp-up of overseas capacity will affect when results materialize.
J.P. Morgan ·
WuXi AppTec’s new orders and early-stage R&D demand are improving; TrendForce expects memory price increases to continue through the first half of 2028. Japanese bank valuations have fallen, while deposit competition at HSBC is weighing on net interest income expectations.
Goldman Sachs ·
Phase III and commercial small-molecule projects are accelerating orders, while early-stage R&D demand is also recovering. Goldman Sachs sees improved revenue visibility for 2027, but the timing of large-order deliveries, capacity expansion and exchange rates could still cause quarterly fluctuations.
Goldman Sachs ·
Third-quarter revenue was broadly in line with Goldman Sachs’ expectations, while adjusted net profit slightly exceeded them. Backlog growth accelerated to 36.4%, and the company raised its full-year revenue, capital expenditure and free cash flow guidance.
Goldman Sachs ·
摩根士丹利将资本开支视为订单与收入增长的领先指标：药明康德2026年预算升至75亿—85亿元，苏州临床前研究与常州生产扩建同步推进。
Morgan Stanley ·
